Quantcast

Latest Myriad Genetics Inc. Stories

2014-08-18 16:28:21

Petitions aim to nullify cancer gene patents owned, co-owned, or licensed by Myriad Genetics, Inc. WASHINGTON, Aug. 18, 2014 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox P.L.L.C., an intellectual property law firm in Washington, DC, announced today that it has filed eleven petitions for Inter Partes Review (IPR) with the U.S. Patent and Trademark Office (USPTO) on behalf of GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI). These IPR petitions aim...

2013-06-13 23:03:37

Plaintiffs, including the American Civil Liberties Union, Association for Molecular Pathology, and American Society for Clinical Pathology, win long-fought case against Myriad Genetics, Association for Molecular Pathology v. Myriad Genetics, Inc. No. 12—398, that has far-reaching possibilities for genetic research and improved patient outcomes. Chicago, IL (PRWEB) June 13, 2013 The U.S. Supreme Court today invalidated patents on two genes associated with hereditary breast and ovarian...

Biotech Firm Loses Supreme Court Fight To Patent Human Genes
2013-06-13 12:24:31

Lawrence LeBlond for redOrbit.com - Your Universe Online A Salt Lake City, Utah-based genetics firm has lost a battle in court to keep a patent on naturally-occurring human genes. The US Supreme Court has shot down Myriad Genetics Inc.´s bid to patent breast and ovarian cancer genes, ruling that human genes cannot be patented. The decision has immediate benefits for some cancer patients but may have long-lasting repercussions for biotechnology research. The decision, written up...

2009-09-14 08:00:00

SALT LAKE CITY, Sept. 14 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has launched a hereditary breast and ovarian cancer Public Awareness Campaign in five Midwest states, including Illinois, Indiana, Kentucky, Missouri and Ohio. The initiative is a comprehensive effort designed to reach women with a family history of breast and/or ovarian cancers and the healthcare providers that treat them. According to the American Cancer Society, more than...

2008-11-04 06:00:33

Myriad Genetics, Inc. (NASDAQ: MYGN) today reported its first profitable quarter from operations. The Company recorded a net profit of $14.5 million, or $0.32 basic earnings per share ($0.30 diluted earnings per share), compared to a net loss of $8.0 million and loss per share of $0.18 in the same quarter of the prior year. A major contributor to the Company's profitable quarter was its molecular diagnostics business, which achieved a net operating margin of 46%, a significant improvement...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related